Session » Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Date: Sunday, November 8, 2015

Time: 2:30PM-4:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 955

Cancer Risk in 5,108 Patients with Juvenile Idiopathic Arthritis (JIA)

2:30PM-4:00PM: Abstract Number: 957

Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters

2:30PM-4:00PM: Abstract Number: 960

Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics

2:30PM-4:00PM: Abstract Number: 959

Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study

2:30PM-4:00PM: Abstract Number: 956

The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events

2:30PM-4:00PM: Abstract Number: 958

The Time Spent in Inactive Disease before MTX Withdrawal Is Relevant with Regard to the Recurrence of Active Disease in Juvenile Idiopathic Arthritis (JIA) Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].